DOCSLIB.ORG

Impaired FGF Signaling Contributes to Cleft Lip and Palate

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Impaired FGF Signaling Contributes to Cleft Lip and Palate Impaired FGF signaling contributes to cleft lip and palate Bridget M. Riley*, M. Adela Mansilla*, Jinghong Ma†, Sandra Daack-Hirsch*, Brion S. Maher‡, Lisa M. Raffensperger*, Erilynn T. Russo*, Alexandre R. Vieira‡, Catherine Dode´ §, Moosa Mohammadi†, Mary L. Marazita‡¶, and Jeffrey C. Murray*ʈ *Department of Pediatrics, University of Iowa, Iowa City, IA 52242; †Department of Pharmacology, New York University School of Medicine, New York, NY 10016; ‡Center for Craniofacial and Dental Genetics, Department of Oral Biology, School of Dental Medicine, University of Pittsburgh, Pittsburgh, PA 15219; §Institut Cochin et Laboratoire de Biochimie et Ge´ne´ tique Mole´culaire, Hoˆpital Cochin, 75014 Paris, France; and ¶Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15219 Edited by Mary-Claire King, University of Washington, Seattle, WA, and approved January 18, 2007 (received for review September 12, 2006) Nonsyndromic cleft lip and palate (NS CLP) is a complex birth defect plasia syndromes (FGFR1–FGFR3) and Kallmann syndrome resulting from a combination of genetic and environmental factors. (KS) (FGFR1). Cleft palate occurs in 44% of cases of Apert Several members of the FGF and FGFR families are expressed syndrome, which is characterized by combined craniosynostosis during craniofacial development and can rarely harbor mutations and syndactyly (12, 13). Two mutations in the FGFR2 gene, that result in human clefting syndromes. We hypothesized that S252W and P253R, account for almost all cases of Apert disruptions in this pathway might also contribute to NS CLP. We syndrome; the clefting phenotype is more commonly associated sequenced the coding regions and performed association testing with the S252W mutation (59%) than with the P253R mutation on 12 genes (FGFR1, FGFR2, FGFR3, FGF2, FGF3, FGF4, FGF7, FGF8, (17%) (12, 14). The autosomal-dominant KS, whose main fea- FGF9, FGF10, FGF18, and NUDT6) and used protein structure anal- tures are anosmia and hypogonadotrophic hypogonadism, is yses to predict the function of amino acid variants. Seven likely caused by loss-of-function mutations in FGFR1, and 5–10% of disease-causing mutations were identified, including: one non- these patients have a cleft (unpublished estimate) (15–17). sense mutation (R609X) in FGFR1, a de novo missense mutation Additionally, mutations in FGF10 are associated with autoso- (D73H) in FGF8, and other missense variants in FGFR1, FGFR2, and mal-dominant aplasia of lacrimal and salivary glands (18). FGFR3. Structural analysis of FGFR1, FGFR2, and FGF8 variants Animal models also support the involvement of FGFs and suggests that these mutations would impair the function of the FGFRs in the pathogenesis of CLP. Fgf10Ϫ/Ϫ (19), Fgfr2bϪ/Ϫ proteins, albeit through different mechanisms. Genotyping of SNPs (20), Fgf18Ϫ/Ϫ (21, 22), and Fgfr1 hypomorphic mice have cleft in the genes found associations between NS CLP and SNPs in FGF3, palate (23). Hypomorphic Fgf8neo/Ϫ mutant mice have cranio- FGF7, FGF10, FGF18, and FGFR1. The data suggest that the FGF facial defects, including abnormal development of the palate and signaling pathway may contribute to as much as 3–5% of NS CLP palatine bones (24). Moreover, disruption of the directional and will be a consideration in the clinical management of CLP. epithelial-mesenchymal Fgf10-Fgfr2b signaling has been found to result in cleft palate in mice (19). In this report, we provide fibroblast growth factor ͉ fibroblast growth factor receptor ͉ direct sequencing and association data showing that disruptions single-nucleotide polymorphism ͉ cleft palate in FGF signaling also contribute to CLP in humans. Results solated or nonsyndromic cleft lip and palate (NS CLP) is a Ϸ Icommon congenital anomaly affecting Ϸ1/700 live births Sequencing. Overall, 84 amplicons encoding 33,000 base pairs worldwide, although prevalence varies widely based on geo- were sequenced for the 12 FGF and FGFR genes in genomic graphic and socioeconomic status (1, 2). Significantly increased DNA for 184 individuals with NS CLP [see supporting infor- lifetime mortality ratios of 1.4 for males and 1.8 for females are mation (SI) Table 3]. Thirty-seven point mutations were iden- associated with NS CLP (3). Additionally, clefting requires tified in the exons or at the intron–exon junctions of the FGF and extensive medical interventions that create significant economic FGFR genes examined in families with NS CLP from both Iowa and social burdens for family and society (4). (16) and the Philippines (20). All mutations appear in SI Table Both genetic and environmental factors are known to play a 4, and the nine missense and nonsense mutations are listed in role in the development of NS CLP, complicating the identifi- Table 1. SI Table 5 contains the predictions from exon splice- cation of causal genes. A study examining recurrence patterns of enhancer programs on the effects of the synonymous mutations NS CLP estimated that as many as 14 interacting loci may be identified in the coding regions. None of these mutations has involved in clefting (5). Prior sequencing analysis of DNA been previously reported in the SNP database (dbSNP). When samples from NS CLP cases has indicated minor roles for we excluded from the analysis the initial ascertainment cases and mutations in MSX1, FOXE1, GLI2, MSX2, SKI, and SPRY2 in the etiology of NS CLP (6–8). Additionally, polymorphisms in Author contributions: B.M.R. and J.C.M. designed research; B.M.R., M.A.M., J.M., S.D.-H., the IRF6 gene have been found to be strongly associated with NS B.S.M., L.M.R., E.T.R., A.R.V., M.M., and M.L.M. performed research; C.D. contributed new CLP, accounting for Ϸ12% of clefting (9). reagents/analytic tools; B.M.R., M.A.M., B.S.M., L.M.R., E.T.R., A.R.V., M.M., M.L.M., and Mammalian fibroblast growth factors (FGF1–FGF10 and J.C.M. analyzed data; and B.M.R., M.M., M.L.M., and J.C.M. wrote the paper;. FGF16–FGF23) control a wide spectrum of biological functions The authors declare no conflict of interest. during development and adult life (10). The biological activities This article is a PNAS direct submission. of FGFs are conveyed by seven principal FGF receptor tyrosine Freely available online through the PNAS open access option. kinases encoded by four distinct genes (FGFR1–FGFR4). In the Abbreviations: FGFR, fibroblast growth factor receptor; KS, Kallmann syndrome; NS CLP, presence of heparan sulfate proteoglycans, two FGFs bind to two nonsyndromic cleft lip and palate. FGFRs, inducing receptor dimerization and enabling the intra- ʈTo whom correspondence should be addressed: Email: [email protected]. cellular tyrosine kinase domains to transphosphorylate and This article contains supporting information online at www.pnas.org/cgi/content/full/ become activated (11). Human diseases that arise from dysregu- 0607956104/DC1. lated FGF signaling include craniosynostosis and skeletal dys- © 2007 by The National Academy of Sciences of the USA 4512–4517 ͉ PNAS ͉ March 13, 2007 ͉ vol. 104 ͉ no. 11 www.pnas.org͞cgi͞doi͞10.1073͞pnas.0607956104 Downloaded by guest on September 26, 2021 Table 1. Missense and nonsense mutations in FGF pathway genes identified in NS CLP patients Gene Mutation Population Phenotype Frequency Control frequency UCSC browser position* FGFR1 M369I Philippine CPO UL CLP 2/1117 0/1368 Chr 8: 38,396,385 FGFR1 E467K Philippine UL CLP 2/1117 0/1384 Chr 8: 38,394,934 FGFR1 R609X Iowa UL CLP BL CLP 1/90 0/91 Chr 8: 38,392,574 FGFR2 D138N Philippine UL CLP BL CLP 5/1027 0/1392 Chr 10: 123,314,048 FGFR2 R84S Iowa BL CLP 1/362 0/1328 Chr 10: 123,315,066 FGFR3 V329I Philippine UL CL UL CLP BL CLP 8/977 5/961 Chr 4: 1,772,704 FGF8 D73H (de novo) Iowa BL CLP 1/262 0/1110 Chr 10: 103,524,599 FGF10 S59F Philippine BL CLP 2/91 3/83 Chr 5: 44,424,366 NUDT6 K172N Iowa Untyped CLP 1/87 0/89 Chr 4: 124,1276,421 CPO, cleft palate only; UL, unilateral; BL, bilateral; CL, cleft lip; CLP, cleft lip and palate; Untyped, cleft lip laterality unknown. *UCSC browser position from the May 2004 assembly. did a formal case-control study looking for the presence of maps to the intracellular juxtamembrane domain that links the M369I, E467K, R84S, D138N, V329I, and D73H, we found a transmembrane helix to the tyrosine kinase domain of FGFR1. significant difference between mutations in cases versus controls Both the M369 and E467 are conserved among the human, (P ϭ 0.04). The protein sequence-altering mutations are more chimp, mouse, rat, and chicken protein sequences (Fig. 2B). In common in cases of NS SLP than in controls. the crystal structure of the FGFR1 kinase domain, E467 is Two FGFR1 mutations, M369I and E467K, were identified in completely solvent-exposed and does not participate in the pedigrees from the Philippines. The M369I mutation was found overall folding of the FGFR1 kinase domain (Fig. 2A). Inter- in two unrelated families (SI Fig. 6). One family had three estingly, however, E467 is located four residues C terminal to affected siblings, as well as one unaffected sibling and an Y463, one of the main tyrosine phosphorylation sites of FGFR1. unaffected mother, each with the mutation. The father was Phosphorylated Y463 has been implicated in the binding and unavailable, but a paternal brother with a cleft did not have the phosphorylation of the SH2 containing signaling molecules such mutation. The E467K mutation was also found in cases from two as Crk and is part of the recognition sequence Y-E-L-P, a unrelated families (SI Fig. 7). In one family, the E467K was preferred binding motif for Crk SH2 domain (26, 27).
Load more

Recommended publications
  • ARTICLES Fibroblast Growth Factors 1, 2, 17, and 19 Are The
    0031-3998/07/6103-0267 PEDIATRIC RESEARCH Vol. 61, No. 3, 2007 Copyright © 2007 International Pediatric Research Foundation, Inc. Printed in U.S.A. ARTICLES Fibroblast Growth Factors 1, 2, 17, and 19 Are the Predominant FGF Ligands Expressed in Human Fetal Growth Plate Cartilage PAVEL KREJCI, DEBORAH KRAKOW, PERTCHOUI B. MEKIKIAN, AND WILLIAM R. WILCOX Medical Genetics Institute [P.K., D.K., P.B.M., W.R.W.], Cedars-Sinai Medical Center, Los Angeles, California 90048; Department of Obstetrics and Gynecology [D.K.] and Department of Pediatrics [W.R.W.], UCLA School of Medicine, Los Angeles, California 90095 ABSTRACT: Fibroblast growth factors (FGF) regulate bone growth, (G380R) or TD (K650E) mutations (4–6). When expressed at but their expression in human cartilage is unclear. Here, we deter- physiologic levels, FGFR3-G380R required, like its wild-type mined the expression of entire FGF family in human fetal growth counterpart, ligand for activation (7). Similarly, in vitro cul- plate cartilage. Using reverse transcriptase PCR, the transcripts for tivated human TD chondrocytes as well as chondrocytes FGF1, 2, 5, 8–14, 16–19, and 21 were found. However, only FGF1, isolated from Fgfr3-K644M mice had an identical time course 2, 17, and 19 were detectable at the protein level. By immunohisto- of Fgfr3 activation compared with wild-type chondrocytes and chemistry, FGF17 and 19 were uniformly expressed within the showed no receptor activation in the absence of ligand (8,9). growth plate. In contrast, FGF1 was found only in proliferating and hypertrophic chondrocytes whereas FGF2 localized predominantly to Despite the importance of the FGF ligand for activation of the resting and proliferating cartilage.
    [Show full text]
  • Disruption of Fibroblast Growth Factor Signal
    Cancer Therapy: Preclinical Disruption of Fibroblast Growth Factor Signal Pathway Inhibits the Growth of Synovial Sarcomas: Potential Application of Signal Inhibitors to MolecularTarget Therapy Ta t s u y a I s hi b e , 1, 2 Tomitaka Nakayama,2 Ta k e s h i O k a m o t o, 1, 2 Tomoki Aoyama,1Koichi Nishijo,1, 2 Kotaro Roberts Shibata,1, 2 Ya s u ko Shim a ,1, 2 Satoshi Nagayama,3 Toyomasa Katagiri,4 Yusuke Nakamura, 4 Takashi Nakamura,2 andJunya Toguchida 1 Abstract Purpose: Synovial sarcoma is a soft tissue sarcoma, the growth regulatory mechanisms of which are unknown.We investigatedthe involvement of fibroblast growth factor (FGF) signals in synovial sarcoma andevaluatedthe therapeutic effect of inhibiting the FGF signal. Experimental Design:The expression of 22 FGF and4 FGF receptor (FGFR) genes in18prima- ry tumors andfive cell lines of synovial sarcoma were analyzedby reverse transcription-PCR. Effects of recombinant FGF2, FGF8, andFGF18 for the activation of mitogen-activatedprotein kinase (MAPK) andthe growth of synovial sarcoma cell lines were analyzed.Growth inhibitory effects of FGFR inhibitors on synovial sarcoma cell lines were investigated in vitro and in vivo. Results: Synovial sarcoma cell lines expressedmultiple FGF genes especially those expressed in neural tissues, among which FGF8 showedgrowth stimulatory effects in all synovial sarcoma cell lines. FGF signals in synovial sarcoma induced the phosphorylation of extracellular signal ^ regulatedkinase (ERK1/2) andp38MAPK but not c-Jun NH 2-terminal kinase. Disruption of the FGF signaling pathway in synovial sarcoma by specific inhibitors of FGFR causedcell cycle ar- rest leading to significant growth inhibition both in vitro and in vivo.Growthinhibitionbythe FGFR inhibitor was associatedwith a down-regulation of phosphorylatedERK1/2 but not p38MAPK, andan ERK kinase inhibitor also showedgrowth inhibitory effects for synovial sar- coma, indicating that the growth stimulatory effect of FGF was transmitted through the ERK1/2.
    [Show full text]
  • Different Fgfs Have Distinct Roles in Regulating Neurogenesis After Spinal Cord Injury in Zebrafish Yona Goldshmit1,2, Jean Kitty K
    Goldshmit et al. Neural Development (2018) 13:24 https://doi.org/10.1186/s13064-018-0122-9 RESEARCHARTICLE Open Access Different Fgfs have distinct roles in regulating neurogenesis after spinal cord injury in zebrafish Yona Goldshmit1,2, Jean Kitty K. Y. Tang1, Ashley L. Siegel1, Phong D. Nguyen1, Jan Kaslin1, Peter D. Currie1 and Patricia R. Jusuf1,3* Abstract Background: Despite conserved developmental processes and organization of the vertebrate central nervous system, only some vertebrates including zebrafish can efficiently regenerate neural damage including after spinal cord injury. The mammalian spinal cord shows very limited regeneration and neurogenesis, resulting in permanent life-long functional impairment. Therefore, there is an urgent need to identify the cellular and molecular mechanisms that can drive efficient vertebrate neurogenesis following injury. A key pathway implicated in zebrafish neurogenesis is fibroblast growth factor signaling. Methods: In the present study we investigated the roles of distinctfibroblastgrowthfactormembersandtheir receptors in facilitating different aspects of neural development and regeneration at different timepoints following spinal cord injury. After spinal cord injury in adults and during larval development, loss and/or gain of Fgf signaling was combined with immunohistochemistry, in situ hybridization and transgenes marking motor neuron populations in in vivo zebrafish and in vitro mammalian PC12 cell culture models. Results: Fgf3 drives neurogenesis of Islet1 expressing motor neuron subtypes and mediate axonogenesis in cMet expressing motor neuron subtypes. We also demonstrate that the role of Fgf members are not necessarily simple recapitulating development. During development Fgf2, Fgf3 and Fgf8 mediate neurogenesis of Islet1 expressing neurons and neuronal sprouting of both, Islet1 and cMet expressing motor neurons.
    [Show full text]
  • FGF Signaling Network in the Gastrointestinal Tract (Review)
    163-168 1/6/06 16:12 Page 163 INTERNATIONAL JOURNAL OF ONCOLOGY 29: 163-168, 2006 163 FGF signaling network in the gastrointestinal tract (Review) MASUKO KATOH1 and MASARU KATOH2 1M&M Medical BioInformatics, Hongo 113-0033; 2Genetics and Cell Biology Section, National Cancer Center Research Institute, Tokyo 104-0045, Japan Received March 29, 2006; Accepted May 2, 2006 Abstract. Fibroblast growth factor (FGF) signals are trans- Contents duced through FGF receptors (FGFRs) and FRS2/FRS3- SHP2 (PTPN11)-GRB2 docking protein complex to SOS- 1. Introduction RAS-RAF-MAPKK-MAPK signaling cascade and GAB1/ 2. FGF family GAB2-PI3K-PDK-AKT/aPKC signaling cascade. The RAS~ 3. Regulation of FGF signaling by WNT MAPK signaling cascade is implicated in cell growth and 4. FGF signaling network in the stomach differentiation, the PI3K~AKT signaling cascade in cell 5. FGF signaling network in the colon survival and cell fate determination, and the PI3K~aPKC 6. Clinical application of FGF signaling cascade in cell polarity control. FGF18, FGF20 and 7. Clinical application of FGF signaling inhibitors SPRY4 are potent targets of the canonical WNT signaling 8. Perspectives pathway in the gastrointestinal tract. SPRY4 is the FGF signaling inhibitor functioning as negative feedback apparatus for the WNT/FGF-dependent epithelial proliferation. 1. Introduction Recombinant FGF7 and FGF20 proteins are applicable for treatment of chemotherapy/radiation-induced mucosal injury, Fibroblast growth factor (FGF) family proteins play key roles while recombinant FGF2 protein and FGF4 expression vector in growth and survival of stem cells during embryogenesis, are applicable for therapeutic angiogenesis. Helicobacter tissues regeneration, and carcinogenesis (1-4).
    [Show full text]
  • Age-Driven Developmental Drift in the Pathogenesis of Idiopathic Pulmonary Fibrosis
    BACK TO BASICS INTERSTITIAL LUNG DISEASES | Age-driven developmental drift in the pathogenesis of idiopathic pulmonary fibrosis Moisés Selman1, Carlos López-Otín2 and Annie Pardo3 Affiliations: 1Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico city, Mexico. 2Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Spain. 3Facultad de Ciencias, Universidad Nacional Autónoma de México, Mexico city, Mexico. Correspondence: Moisés Selman, Instituto Nacional de Enfermedades Respiratorias, Tlalpan 4502, CP 14080, México DF, México. E-mail: [email protected] ABSTRACT Idiopathic pulmonary fibrosis (IPF) is a progressive and usually lethal disease of unknown aetiology. A growing body of evidence supports that IPF represents an epithelial-driven process characterised by aberrant epithelial cell behaviour, fibroblast/myofibroblast activation and excessive accumulation of extracellular matrix with the subsequent destruction of the lung architecture. The mechanisms involved in the abnormal hyper-activation of the epithelium are unclear, but we propose that recapitulation of pathways and processes critical to embryological development associated with a tissue specific age-related stochastic epigenetic drift may be implicated. These pathways may also contribute to the distinctive behaviour of IPF fibroblasts. Genomic and epigenomic studies have revealed that wingless/ Int, sonic hedgehog and other developmental signalling pathways are reactivated and deregulated in IPF. Moreover, some of these pathways cross-talk with transforming growth factor-β activating a profibrotic feedback loop. The expression pattern of microRNAs is also dysregulated in IPF and exhibits a similar expression profile to embryonic lungs. In addition, senescence, a process usually associated with ageing, which occurs early in alveolar epithelial cells of IPF lungs, likely represents a conserved programmed developmental mechanism.
    [Show full text]
  • The Biology of Hepatocellular Carcinoma: Implications for Genomic and Immune Therapies Galina Khemlina1,4*, Sadakatsu Ikeda2,3 and Razelle Kurzrock2
    Khemlina et al. Molecular Cancer (2017) 16:149 DOI 10.1186/s12943-017-0712-x REVIEW Open Access The biology of Hepatocellular carcinoma: implications for genomic and immune therapies Galina Khemlina1,4*, Sadakatsu Ikeda2,3 and Razelle Kurzrock2 Abstract Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, is a leading cause of cancer-related death worldwide. It is highly refractory to most systemic therapies. Recently, significant progress has been made in uncovering genomic alterations in HCC, including potentially targetable aberrations. The most common molecular anomalies in this malignancy are mutations in the TERT promoter, TP53, CTNNB1, AXIN1, ARID1A, CDKN2A and CCND1 genes. PTEN loss at the protein level is also frequent. Genomic portfolios stratify by risk factors as follows: (i) CTNNB1 with alcoholic cirrhosis; and (ii) TP53 with hepatitis B virus-induced cirrhosis. Activating mutations in CTNNB1 and inactivating mutations in AXIN1 both activate WNT signaling. Alterations in this pathway, as well as in TP53 and the cell cycle machinery, and in the PI3K/Akt/mTor axis (the latter activated in the presence of PTEN loss), as well as aberrant angiogenesis and epigenetic anomalies, appear to be major events in HCC. Many of these abnormalities may be pharmacologically tractable. Immunotherapy with checkpoint inhibitors is also emerging as an important treatment option. Indeed, 82% of patients express PD-L1 (immunohistochemistry) and response rates to anti-PD-1 treatment are about 19%, and include about 5% complete remissions as well as durable benefit in some patients. Biomarker-matched trials are still limited in this disease, and many of the genomic alterations in HCC remain challenging to target.
    [Show full text]
  • Regulation of Fibroblast Growth Factor-2 Expression and Cell Cycle Progression by an Endogenous Antisense RNA
    Genes 2012, 3, 505-520; doi:10.3390/genes3030505 OPEN ACCESS genes ISSN 2073-4425 www.mdpi.com/journal/genes Article Regulation of Fibroblast Growth Factor-2 Expression and Cell Cycle Progression by an Endogenous Antisense RNA Mark Baguma-Nibasheka, Leigh Ann MacFarlane and Paul R. Murphy * Department of Physiology and Biophysics, Faculty of Medicine, Dalhousie University, 5850 College Street, Halifax, NS B3H 4R2, Canada; E-Mails: [email protected] (M.B.-N.); [email protected] (L.A.M.) * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-902-494-1579; Fax: +1-902-494-2050. Received: 27 June 2012; in revised form: 31 July 2012 / Accepted: 15 August 2012 / Published: 16 August 2012 Abstract: Basic fibroblast growth factor (FGF2) is a potent wide-spectrum mitogen whose overexpression is associated with immortalization and unregulated cell proliferation in many tumors. The FGF2 gene locus is bi-directionally transcribed to produce FGF2 P51$IURPWKH³VHQVH´VWUDQGDQGDcis-antisense RNA (NUDT6) from the NUDT6 gene RQWKH³DQWLVHQVH´VWUDQG7KH18'7JHQHHQFRGHVDQXGL[PRWLISURWHLQRIXQNQRZQ function, while its mRNA has been implicated in the post-transcriptional regulation of FGF2 expression. FGF2 and NUDT6 are co-expressed in rat C6 glioma cells, and ectopic overexpression of NUDT6 suppresses cellular FGF2 accumulation and cell cycle progression. However, the role of the endogenous antisense RNA in regulation of FGF2 is unclear. In the present study, we employed siRNA-mediated gene knockdown to examine the role of the endogenous NUDT6 RNA in regulation of FGF2 expression and cell cycle progression. Knockdown of either FGF2 or NUDT6 mRNA was accompanied by a significant (>3 fold) increase in the complementary partner RNA.
    [Show full text]
  • The Roles of Fgfs in the Early Development of Vertebrate Limbs
    Downloaded from genesdev.cshlp.org on September 26, 2021 - Published by Cold Spring Harbor Laboratory Press REVIEW The roles of FGFs in the early development of vertebrate limbs Gail R. Martin1 Department of Anatomy and Program in Developmental Biology, School of Medicine, University of California at San Francisco, San Francisco, California 94143–0452 USA ‘‘Fibroblast growth factor’’ (FGF) was first identified 25 tion of two closely related proteins—acidic FGF and ba- years ago as a mitogenic activity in pituitary extracts sic FGF (now designated FGF1 and FGF2, respectively). (Armelin 1973; Gospodarowicz 1974). This modest ob- With the advent of gene isolation techniques it became servation subsequently led to the identification of a large apparent that the Fgf1 and Fgf2 genes are members of a family of proteins that affect cell proliferation, differen- large family, now known to be comprised of at least 17 tiation, survival, and motility (for review, see Basilico genes, Fgf1–Fgf17, in mammals (see Coulier et al. 1997; and Moscatelli 1992; Baird 1994). Recently, evidence has McWhirter et al. 1997; Hoshikawa et al. 1998; Miyake been accumulating that specific members of the FGF 1998). At least five of these genes are expressed in the family function as key intercellular signaling molecules developing limb (see Table 1). The proteins encoded by in embryogenesis (for review, see Goldfarb 1996). Indeed, the 17 different FGF genes range from 155 to 268 amino it may be no exaggeration to say that, in conjunction acid residues in length, and each contains a conserved with the members of a small number of other signaling ‘‘core’’ sequence of ∼120 amino acids that confers a com- molecule families [including WNT (Parr and McMahon mon tertiary structure and the ability to bind heparin or 1994), Hedgehog (HH) (Hammerschmidt et al.
    [Show full text]
  • Thymic Mesenchymal Cells Have a Distinct Transcriptomic Profile
    Thymic Mesenchymal Cells Have a Distinct Transcriptomic Profile Julien Patenaude and Claude Perreault This information is current as J Immunol 2016; 196:4760-4770; Prepublished online 29 of October 1, 2021. April 2016; doi: 10.4049/jimmunol.1502499 http://www.jimmunol.org/content/196/11/4760 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2016/04/29/jimmunol.150249 Material 9.DCSupplemental References This article cites 65 articles, 18 of which you can access for free at: http://www.jimmunol.org/content/196/11/4760.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on October 1, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Thymic Mesenchymal Cells Have a Distinct Transcriptomic Profile Julien Patenaude and Claude Perreault In order to understand the role of mesenchymal cells (MCs) in the adult thymus, we performed whole transcriptome analyses of primary thymic, bone, and skin MCs.
    [Show full text]
  • The FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives
    cancers Review The FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives Maria Francesca Santolla and Marcello Maggiolini * Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy; [email protected] * Correspondence: [email protected] or [email protected] Received: 8 September 2020; Accepted: 16 October 2020; Published: 18 October 2020 Simple Summary: The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) system represents an emerging therapeutic target in breast cancer. Here, we discussed previous studies dealing with FGFR molecular aberrations, the alterations in the FGF/FGFR signaling across the different subtypes of breast cancer, the functional interplay between the FGF/FGFR axis and important components of the breast microenvironment, the therapeutic usefulness of FGF/FGFR inhibitors for the treatment of breast cancer. Abstract: One of the major challenges in the treatment of breast cancer is the heterogeneous nature of the disease. With multiple subtypes of breast cancer identified, there is an unmet clinical need for the development of therapies particularly for the less tractable subtypes. Several transduction mechanisms are involved in the progression of breast cancer, therefore making the assessment of the molecular landscape that characterizes each patient intricate. Over the last decade, numerous studies have focused on the development of tyrosine kinase inhibitors (TKIs) to target the main pathways dysregulated in breast cancer, however their effectiveness is often limited either by resistance to treatments or the appearance of adverse effects. In this context, the fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) system represents an emerging transduction pathway and therapeutic target to be fully investigated among the diverse anti-cancer settings in breast cancer.
    [Show full text]
  • A Novel Regulatory Mechanism for Fgf18 Signaling Involving Cysteine
    RESEARCH ARTICLE 159 Development 137, 159-167 (2010) doi:10.1242/dev.041574 A novel regulatory mechanism for Fgf18 signaling involving cysteine-rich FGF receptor (Cfr) and delta-like protein (Dlk) Yuichiro Miyaoka1, Minoru Tanaka2, Toru Imamura3, Shinji Takada4,5 and Atsushi Miyajima1,* SUMMARY Fibroblast growth factors (FGFs) transduce signals through FGF receptors (FGFRs) and have pleiotropic functions. Besides signal- transducing FGFRs, cysteine-rich FGF receptor (Cfr; Glg1) is also known to bind some FGFs, although its physiological functions remain unknown. In this study, we generated Cfr-deficient mice and found that some of them die perinatally, and show growth retardation, tail malformation and cleft palate. These phenotypes are strikingly similar to those of Fgf18-deficient mice, and we revealed interaction between Cfr and Fgf18 both genetically and physically, suggesting functional cooperation. Consistently, introduction of Cfr facilitated Fgf18-dependent proliferation of Ba/F3 cells expressing Fgfr3c. In addition, we uncovered binding between Cfr and delta-like protein (Dlk), and noticed that Cfr-deficient mice are also similar to Dlk-transgenic mice, indicating that Cfr and Dlk function in opposite ways. Interestingly, we also found that Dlk interrupts the binding between Cfr and Fgf18. Thus, the Fgf18 signaling pathway seems to be finely tuned by Cfr and Dlk for skeletal development. This study reveals a novel regulatory mechanism for Fgf18 signaling involving Cfr and Dlk. KEY WORDS: Cysteine-rich FGF receptor (Cfr), Delta-like protein (Dlk), Fibroblast growth factor 18 (Fgf18) INTRODUCTION signaling (Trueb et al., 2003), and has indispensable roles in the The fibroblast growth factor (FGF) family consists of 22 members development of the diaphragm (Baertschi et al., 2007).
    [Show full text]
  • Ep 3217179 A1
    (19) TZZ¥ ___T (11) EP 3 217 179 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 13.09.2017 Bulletin 2017/37 G01N 33/68 (2006.01) (21) Application number: 17167637.2 (22) Date of filing: 02.10.2013 (84) Designated Contracting States: • LIU, Xinjun AL AT BE BG CH CY CZ DE DK EE ES FI FR GB San Diego, CA 92130 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • HAUENSTEIN, Scott PL PT RO RS SE SI SK SM TR San Diego, CA 92130 (US) • KIRKLAND, Richard (30) Priority: 05.10.2012 US 201261710491 P San Diego, CA 92111 (US) 17.05.2013 US 201361824959 P (74) Representative: Krishnan, Sri (62) Document number(s) of the earlier application(s) in Nestec S.A. accordance with Art. 76 EPC: Centre de Recherche Nestlé 13779638.9 / 2 904 405 Vers-chez-les-Blanc Case Postale 44 (71) Applicant: Nestec S.A. 1000 Lausanne 26 (CH) 1800 Vevey (CH) Remarks: (72) Inventors: This application was filed on 21-04-2017 as a • SINGH, Sharat divisional application to the application mentioned Rancho Santa Fe, CA 92127 (US) under INID code 62. (54) METHODS FOR PREDICTING AND MONITORING MUCOSAL HEALING (57) The present invention provides methods for pre- an individual with a disease such as IBD. Information on dicting the likelihood of mucosal healing in an individual mucosal healing status derived from the use of the with a disease such as inflammatory bowel disease present invention can also aid in optimizing therapy (IBD).
    [Show full text]